Biotest increases EBITDA by 52% to EUR 8.8 million in the first half of the year (German)

Profit before interest, taxes, depreciation and amortization ^

DGAP-News: Biotest AG / Keywords: Semi-annual results

Biotest AG: Biotest increases EBITDA by 52% to EUR 8.8 million in the first half of the year

27/07/2022 / 08:30

The best jobs of the day

Find the best job offers now and
be notified by e-mail.

The issuer / publisher is responsible for the content of the application.

————————————————– —————————————

PRESS RELEASE

Biotest increases EBITDA by 52% to EUR 8.8 million in the first half of the year

* In a difficult environment, Biotest almost achieved sales from the previous year

* Opening of 4 plasma collection points in the first half of the year

* More plasma centers planned for 2022

Dreieich, July 28, 2022 In the first half of the fiscal year 2022

The Biotest Group achieved sales of EUR 253.1 million. This is data

difficult global economic situation, the pandemic of the crown and

difficult supply of human plasma more than satisfactory. FROM

year-on-year decrease by EUR 257.8 million

1.8%.

Profit before interest, taxation, depreciation (EBITDA) was

In the first half of the financial year 2022 to EUR 8.8 million, EUR 5.8 million in the first

six months of the previous year. This corresponds to an increase of 51.7%.

EBIT in the first half of 2022 amounted to EUR 9.1 million and thus amounted to

below last year’s value – EUR 8.5 million. This year they are in it

Expenditure on the Biotest Next Level project in the amount of EUR 41.5 million

of which (previous year: EUR 38.0 million).

It is characterized by a global increase in the demand for immunoglobulins

while the pandemic was still severe, Biotest was able to:

the adjusted pricing policy will in particular increase the sales of Intratec®.

This development, however, may reduce sales in the rest

product areas do not fully balance each other.

During the reporting period, Biotest AG was already able to open a fourth one

are implementing new plasma collection centers. Moreover, other new ones

planned plasma centers in 2022 to increase plasma supply to

providing a broader base.

Full data will be available for the first half of fiscal year 2022

Publish Biotest on August 11, 2022.

About Biotest

Biotest is a supplier of plasma proteins and biotherapeutics

anxieties. With a value chain that stretches from preclinical research and

from clinical development to global marketing

Biotest primarily in the areas of clinical immunology applications,

He specializes in hematology, intensive care and emergency medicine. biotest

develops and sells immunoglobulins, coagulation factors and albumin,

which are produced on the basis of human blood plasma and

Diseases of the immune system or the hematopoietic system are used

come on. Biotest employs over 2,000 people worldwide. stalk

and the preferred shares of Biotest AG are in the Prime Standard of the German Stock Exchange

listed.

IR contact:

Dr. Monica Buttkereit

Phone: + 49-6103-801-4406

E-mail: [email protected]

PR contact:

Dirk Neumuller

Telephone: +49 -6103-801-269

E-mail: [email protected]

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.com

Ordinary action: WKN: 522720; ISIN: DE0005227201

Preferred share: WKN: 522723; ISIN: DE0005227235

Listed: Frankfurt (highest standard)

Open Market: Berlin, Düsseldorf, Hamburg / Hanover, Munich, Stuttgart,

Tradegate

Reservation

This document contains forward-looking statements regarding:

general economic development, as well as business, profit and financial development

financial standing of Biotest AG and its subsidiaries. This

Statements are based on current plans, estimates, forecasts and

the expectations of the firm and are therefore at risk and

Uncertainty factors that may lead to the actual

significantly deviates from the expected development. Looking to the future

Statements are only valid at the time of publication. biotest

does not intend to update any forward-looking statements i

bears no obligation for this.

————————————————– —————————————

07/28/2022 publication of corporate news / financial announcement,

provided by DGAP – EQS Group AG service.

The issuer / publisher is responsible for the content of the application.

DGAP’s distribution services include statutory reporting requirements,

Corporate / financial news and press releases.

Media archive at http://www.dgap.de

————————————————– —————————————

German

Company: Biotest AG

Landsteinerstraße 5

63303 Dreieich

Germany

Phone: 0 61 03 – 8 01-0

Fax: 0 61 03 – 8 01-150

E-mail: [email protected]

Internet: www.biotest.de

ISIN: DE0005227235, DE0005227201

WKN: 522723, 522720

Exchanges: Regulated market in Frankfurt (Prime Standard);

Open market in Berlin, Dusseldorf, Hamburg, Hannover,

Munich, Stuttgart, Tradegate Exchange

EQS message ID: 1406293

End of news DGAP news service

————————————————– —————————————

1406293 28/07/2022

°

Leave a Comment